SynthesisTuberculosis (Edinburgh, Scotland)2015
Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.
Synthesis in Tuberculosis (Edinburgh, Scotland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies.The Lancet. Respiratory medicine · 2024Pooled it
- A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021Trial
- Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients.BMC infectious diseases · 2025Article
- The impact of population aging on tuberculosis prevention and control in Shanghai: a prediction based on age-period-cohort models.Aging clinical and experimental research · 2025Article
- Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Article
- High all-cause mortality and increasing proportion of older adults with tuberculosis in Texas, 2008-2020.Epidemiology and infection · 2024Article
- Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study.BMC medical research methodology · 2024Article
- Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.Drug safety · 2024Article
- Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study.Infectious disease reports · 2023Article
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis.Gastroenterology and hepatology from bed to bench · 2023Review
- A narrative review of tuberculosis in the United States among persons aged 65 years and older.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Review
- Clinical standards for the dosing and management of TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection.Disease models & mechanisms · 2021Article
- Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Predicting Antituberculosis Drug-Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study.JMIR medical informatics · 2021Article
- Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.BioMed research international · 2020Article
- The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study.Respiratory research · 2019Article
- The role of regular liver function monitoring in antituberculosis drug-induced liver injury.Journal of the Chinese Medical Association : JCMA · 2019Article
- Monitoring tuberculosis contact tracing outcomes in Western Sydney, Australia.BMJ open respiratory research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundElderly persons have the highest rates of tuberculosis (TB) in the United States compared to all other age groups. A systematic literature review was conducted to determine if older age was a risk factor for hepatotoxicity resulting from treatment with first-line drugs used to treat active (TB) and latent tuberculosis (LTBI).
methodsA systematic review of MEDLINE, Cochrane Controlled Trial Registry, CINAHL(®), and Science Citation Index Expanded (from 1970 to 2011) was performed to determine the risk of hepatotoxicity, comparing those over 60 with those under 60. A meta-analysis was performed using a random effects model along with log odds ratios and the chi-square test.
findingsThirty-eight studies (40,034 participants; 1208 cases of hepatotoxicity) met the selection criteria. For active TB, an overall mean effect of 0.277 (p = 0.024, 95% CI: 0.037-0.517) was observed, which is equivalent to an odds ratio of 1.32 (95% CI: 1.04-1.68). For LTBI, an overall mean effect of 1.42 (p < 0.001, 95% CI: 0.794-2.05) was observed, which translates to an odds ratio of 4.14 (95% CI: 2.21-7.74).
interpretationOur analysis revealed that patients older than 60 had significantly more risk of hepatotoxicity. These studies suggest that a gentler regimen of treatment for older individuals could benefit health outcomes in this population of TB patients and minimize risks to the public's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.